<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20967295</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>07</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2017</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1699-3993</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>46</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drugs of today (Barcelona, Spain : 1998)</Title>
          <ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dalfampridine in multiple sclerosis.</ArticleTitle>
        <Pagination>
          <StartPage>635</StartPage>
          <EndPage>639</EndPage>
          <MedlinePgn>635-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1358/dot.2010.46.9.1499027</ELocationID>
        <Abstract>
          <AbstractText>Dalfampridine (4-aminopyridine or 4-AP) is a potassium channel blocker that is historically known in the literature as fampridine (INN). This review begins with an outline of the pharmacology and pharmacokinetics. Early clinical trials are highlighted, followed by a review of the more recent phase II and III placebo-controlled clinical trials that have examined dalfampridine in multiple sclerosis patients. In these trials, extended-release dalfampridine was shown to result in an average 25% increase in the walking speed in more than one-third of the patients who received the drug and met the prescribed criteria for consistent responders. The safety profile of dalfampridine is also reviewed, with a focus on the risk for epileptic seizures as an adverse effect.</AbstractText>
          <CopyrightInformation>Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Goodman</LastName>
            <ForeName>A D</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Rochester, Medical Center, Rochester, New York 14642, USA. andrew_goodman@urmc.rochester.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hyland</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Spain</Country>
        <MedlineTA>Drugs Today (Barc)</MedlineTA>
        <NlmUniqueID>101160518</NlmUniqueID>
        <ISSNLinking>1699-3993</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20967295</ArticleId>
        <ArticleId IdType="doi">10.1358/dot.2010.46.9.1499027</ArticleId>
        <ArticleId IdType="pii">1499027</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
